Review
Medicine, Research & Experimental
Joanna Dulinska-Litewka, Dominik Felkle, Kacper Dykas, Zuzanna Handziuk, Marta Krzysztofik, Bartosz Gasiorkiewicz
Summary: The role of cyclins in hormone-dependent neoplasms, especially breast cancer, is crucial. However, cyclins in prostate cancer are less studied, particularly the role of other cyclins that requires further investigation. Recent studies have shown that cyclins not only regulate the cell cycle but also interact with other signaling pathways. The androgen signaling axis plays a significant role in prostate cancer progression and interferes with cyclin pathways.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Editorial Material
Cell Biology
Li Xin
Summary: EZH2 has been shown to promote the development of castration-resistant prostate cancer (CRPC) by interacting with the androgen receptor (AR) to reprogram its transcriptional activity, facilitating the transition of CRPC into a lineage infidelity state.
NATURE CELL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yongjun Quan, Xiaodong Zhang, William Butler, Zhen Du, Mingdong Wang, Yuexin Liu, Hao Ping
Summary: The dysregulation of androgen receptor signaling is crucial in prostate cancer progression, and targeting N-cadherin may overcome resistance to hormone therapy. N-cadherin collaborates with c-Jun and NDRG1 to promote CRPC progression through EMT, providing insights into potential therapeutic strategies for advanced prostate cancer.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Cell Biology
Katie Joanna Miller, Mohammad Asim
Summary: The androgen receptor (AR) signalling pathway plays a key role in prostate cancer. Upstream kinases promote AR signalling, while other kinases are regulated by AR. These kinases represent potential therapeutic targets for PCa.
Review
Oncology
Carole Luthold, Tarek Hallal, David P. Labbe, Francois Bordeleau
Summary: Prostate cancer affects a large number of men worldwide. Understanding the mechanisms of disease progression and therapy resistance is crucial for developing effective treatments. Alterations in the extracellular matrix, particularly stiffening, play a role in prostate cancer progression. This review examines the association between extracellular matrix stiffening and disease progression and castration resistance in prostate cancer.
Review
Biochemistry & Molecular Biology
Demitria M. Vasilatis, Christopher A. Lucchesi, Paramita M. Ghosh
Summary: Dogs naturally develop prostate cancer similar to aggressive forms found in humans. Prostate cancer samples in dogs often lack androgen receptor (AR), which can enhance our understanding of AR-indifferent prostate cancer in humans. This review highlights the molecular similarities between dog and human prostate cancer variants, suggesting the potential use of dogs as pre-clinical animal models for developing new therapies and diagnostics that can benefit both species.
Article
Biochemistry & Molecular Biology
Jong-Kwang Kim, Jae-Hun Jung, Dong-Hoon Shin, Hye-Jin You, Seho Cha, Bo-Seul Song, Jae-Young Joung, Weon-Seo Park, Kwang-Pyo Kim, Jae-Kyung Myung
Summary: This study characterized the rapid proteomic changes in VCaP cells after androgen treatment, identifying five protein clusters involved in different stages of androgen-initiated signal transmission and processing. The study revealed significant regulation of AR-regulated proteins in CRPC patients and provided a comprehensive perspective on the molecular mechanisms underlying CRPC progression.
Article
Materials Science, Biomaterials
Ze Gao, Jun Huang, Zhaoxiang Xie, Peikun Xin, Hao Huang, Tao Du, Jun Wu, Hai Huang
Summary: This article proposes a strategy of using a biocompatible nanoparticle drug delivery system to improve the bioavailability and therapeutic performance of enzalutamide. The system has been shown to enhance drug delivery efficiency, increase drug cytotoxicity, and reduce the half-inhibitory concentration of the drug, thus demonstrating great potential for the treatment of prostate cancer.
BIOMATERIALS SCIENCE
(2022)
Article
Multidisciplinary Sciences
Nader Al-Nakouzi, Chris Kedong Wang, Htoo Zarni Oo, Irina Nelepcu, Nada Lallous, Charlotte B. Spliid, Nastaran Khazamipour, Joey Lo, Sarah Truong, Colin Collins, Desmond Hui, Shaghayegh Esfandnia, Hans Adomat, Thomas Mandel Clausen, Tobias Gustavsson, Swati Choudhary, Robert Dagil, Eva Corey, Yuzhuo Wang, Anne Chauchereau, Ladan Fazli, Jeffrey D. Esko, Ali Salanti, Peter S. Nelson, Martin E. Gleave, Mads Daugaard
Summary: Inhibition of the androgen receptor pathway leads to the upregulation of chondroitin sulfate (CS), which promotes the growth and metastasis of prostate cancer.
NATURE COMMUNICATIONS
(2022)
Review
Biochemistry & Molecular Biology
Ryan Cronin, Greg N. Brooke, Filippo Prischi
Summary: Prostate cancer is the second most commonly occurring cancer in men, with standard treatments including androgen-deprivation therapy and AR signaling inhibitors. However, the development of therapy resistance can occur. The p90 ribosomal S6 kinase (RSK) family is a potential novel target for treatment, exhibiting roles in transcription and translation regulation.
Article
Biochemistry & Molecular Biology
Vania Camilo, Mariana Bruett Pacheco, Filipa Moreira-Silva, Goncalo Outeiro-Pinho, Vitor M. Gaspar, Joao F. Mano, C. Joana Marques, Rui Henrique, Carmen Jeronimo
Summary: This study investigated the relationship between CpG methylation in the promoter region of androgen receptor (AR) gene and loss of AR expression. The results showed sustained methylation in the proximal promoter region of DU-145 cells, which had high resistance to demethylation treatment. Additionally, repressive histone marks significantly increased at AR region 1 in DU-145 cells after treatment. Therefore, inhibiting histone methyltransferases might hold promise for AR re-expression.
Review
Biochemistry & Molecular Biology
Haozhe Zhang, Yi Zhou, Zengzhen Xing, Rajiv Kumar Sah, Junqi Hu, Hailiang Hu
Summary: This review discusses the close relationship between the evolution of prostate cancer and androgen levels and the status of the androgen receptor. It also explores how alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Marco Bolis, Daniela Bossi, Arianna Vallerga, Valentina Ceserani, Manuela Cavalli, Daniela Impellizzieri, Laura Di Rito, Eugenio Zoni, Simone Mosole, Angela Rita Elia, Andrea Rinaldi, Ricardo Pereira Mestre, Eugenia D'Antonio, Matteo Ferrari, Flavio Stoffel, Fernando Jermini, Silke Gillessen, Lukas Bubendorf, Peter Schraml, Arianna Calcinotto, Eva Corey, Holger Moch, Martin Spahn, George Thalmann, Marianna Kruithof-de Julio, Mark A. Rubin, Jean-Philippe P. Theurillat
Summary: The study integrates a transcriptomics atlas of prostate cancer and validates it with preclinical models and single-cell RNA-seq, revealing the role of EZH2 and macrophage polarization in tumour progression.
NATURE COMMUNICATIONS
(2021)
Review
Oncology
Andrew Hartley, Imran Ahmad
Summary: PPAR gamma plays an important role in prostate cancer progression and its splice variants may have different effects. While it is a potential target for therapy, the clinical use of drugs targeting PPAR gamma is limited by their associated side effects.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Salma Ben-Salem, Varadha Balaji Venkadakrishnan, Hannelore Heemers
Summary: Prostate cancer remains the second leading cause of cancer deaths in Western men, primarily due to its resistance to available treatments. Understanding the molecular shifts that control cell division and proliferation during prostate cancer progression may help overcome treatment resistance. Various factors, including cell cycle dysregulation, androgen receptor, and somatic alterations, play a role in prostate cancer development and resistance to treatment.
ENDOCRINE-RELATED CANCER
(2021)
Review
Oncology
Eva Estebanez-Perpina, Charlotte L. Bevan, Iain J. McEwan
Summary: Prostate cancer is the second most common cancer in men globally, with the major clinical problem being castration-resistant prostate cancer (CRPC), where the androgen receptor remains a key therapy target.
Article
Biochemistry & Molecular Biology
Olayiwola O. Oduwole, Ariel Poliandri, Anthony Okolo, Phil Rawson, Milena Doroszko, Marcin Chrusciel, Nafis A. Rahman, Gilberto Serrano de Almeida, Charlotte L. Bevan, Wolfgang Koechling, Ilpo T. Huhtaniemi
Summary: The study suggests that FSH, rather than LH, may directly stimulate the growth of androgen-independent prostate cancer. Continuous suppression of FSH during GnRH antagonist treatment may offer a therapeutic advantage over agonist in inhibiting tumor growth.
Article
Allergy
Eve Blanquart, Audrey Mandonnet, Marion Mars, Claire Cenac, Nina Anesi, Pascale Mercier, Christophe Audouard, Stephane Roga, Gilberto Serrano de Almeida, Charlotte L. Bevan, Jean-Philippe Girard, Lucette Pelletier, Sophie Laffont, Jean-Charles Guery
Summary: This study investigates the impact of androgens on the development and function of innate lymphoid cells in female lungs. The findings suggest that androgens negatively control innate lymphoid cell homeostasis and inflammation in a cell-intrinsic manner. The inhibitory receptor killer cell lectin-like receptor G1 is found to play a dispensable role in androgen-mediated inhibition of innate lymphoid cells.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Ryan Cronin, Greg N. Brooke, Filippo Prischi
Summary: Prostate cancer is the second most commonly occurring cancer in men, with standard treatments including androgen-deprivation therapy and AR signaling inhibitors. However, the development of therapy resistance can occur. The p90 ribosomal S6 kinase (RSK) family is a potential novel target for treatment, exhibiting roles in transcription and translation regulation.
Review
Biochemical Research Methods
Damien A. Leach, Greg N. Brooke, Charlotte L. Bevan
Summary: COVID-19 symptoms and mortality are largely due to its devastating effects in the lungs caused by the SARS-CoV-2 coronavirus. Steroid hormone receptors play a crucial role in lung development, immune system, and viral infection, which has led to investigations on using steroid receptor ligands to treat COVID-19 in clinical trials.
EXPLORING NUCLEAR RECEPTORS
(2021)
Article
Chemistry, Multidisciplinary
Scott Lovell, Leran Zhang, Thomas Kryza, Anna Neodo, Nathalie Bock, Elena De Vita, Elizabeth D. Williams, Elisabeth Engelsberger, Congyi Xu, Alexander T. Bakker, Maria Maneiro, Reiko J. Tanaka, Charlotte L. Bevan, Judith A. Clements, Edward W. Tate
Summary: Kallikrein-related peptidases (KLKs) play important roles in prostate cancer, with significant decoupling between KLK activity and abundance. The proteolysis of KLK should be considered as an additional parameter for accurate diagnosis and monitoring of PCa, presenting a promising therapeutic target.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2021)
Article
Multidisciplinary Sciences
Shenglin Cai, Thomas Pataillot-Meakin, Akifumi Shibakawa, Ren Ren, Charlotte L. Bevan, Sylvain Ladame, Aleksandar P. Ivanov, Joshua B. Edel
Summary: The study presents a new sensing platform for miRNA detection, offering high sensitivity and specificity directly in human serum, and demonstrating monitoring of miR-141-3p and miR-375-3p in various stages of prostate cancer.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
D. A. Leach, A. Mohr, E. S. Giotis, E. Cil, A. M. Isac, L. L. Yates, W. S. Barclay, R. M. Zwacka, C. L. Bevan, G. N. Brooke
Summary: Antiandrogen treatment reduces TMPRSS2 expression in the lung, decreasing SARS-CoV-2 viral entry and infection, supporting the potential of antiandrogens as a therapeutic approach for COVID-19.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Sharmila Rana, Gabriel N. Valbuena, Ed Curry, Charlotte L. Bevan, Hector C. Keun
Summary: A lack of reliable prognostic biomarkers for distinguishing indolent from aggressive prostate cancer has prompted research into microRNAs (miRs). A systematic review identified 15 miRs consistently associated with disease progression, warranting further investigation into their potential as prognostic PCa biomarkers.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Andrea Mohr, Tianyuan Chu, Christopher T. Clarkson, Greg N. Brooke, Vladimir B. Teif, Ralf M. Zwacka
Summary: The study showed a close relationship between Fas-mediated MSC proliferation and tumor progression in the microenvironment of pancreatic cancer. Patient transcriptomic data indicated that high FasL expression is associated with high levels of MSC markers, IL6, and CCL2.
Review
Oncology
Folake Orafidiya, Lin Deng, Charlotte Lynne Bevan, Claire Emily Fletcher
Summary: Non-coding RNAs play important roles in tumor, especially in response to DNA damage. Studying these non-coding RNAs can help design better treatments and tests for prostate cancer.
Review
Biochemistry & Molecular Biology
Theodora A. Constantin, Kyle K. Greenland, Anabel Varela-Carver, Charlotte L. Bevan
Summary: Transcriptional deregulation is a characteristic feature of various cancer types. In metastatic castration-resistant prostate cancer, the addiction of transcriptional activity to the androgen receptor is maintained in most patients. Transcription associated cyclin-dependent kinases (tCDKs), a group of protein kinases, have shown great potential as therapeutic targets for prostate cancer and other solid tumors.
Review
Virology
Efstathios S. Giotis, Emine Cil, Greg N. Brooke
Summary: COVID-19 has caused over 6.5 million deaths worldwide. The emergence of SARS-CoV-2 variants with increased transmissibility and/or virulence, as well as immune and vaccine escape capabilities, highlights the urgent need for effective antiviral treatments. Men are more susceptible to the virus and have higher rates of severe disease, hospitalization, and mortality, which is associated with sex steroid hormones, particularly androgens. Modulating androgen signaling may be a promising strategy to prevent viral infection and antiandrogens could be used early in COVID-19 to mitigate the disease.
Article
Chemistry, Multidisciplinary
Joseph Broomfield, Melpomeni Kalofonou, Thomas Pataillot-Meakin, Sue M. Powell, Rayzel C. Fernandes, Nicolas Moser, Charlotte L. Bevan, Pantelis Georgiou
Summary: Prostate cancer is the second most common cause of male cancer-related death worldwide. Androgen deprivation therapy is the gold standard for treating advanced prostate cancer, but it often leads to castration-resistant prostate cancer. Detecting relevant biomarkers in the blood of castration-resistant patients could help personalize treatment options.
Review
Oncology
Alison K. Buxton, Salma Abbasova, Charlotte L. Bevan, Damien A. Leach
Summary: This article reviews the microenvironment of liver in prostate cancer, the predisposition of prostate cancer to metastasize to the liver, the response of liver to prostate cancer, and the response of liver to current treatment strategies. Liver metastasis is associated with the worst clinical outcomes for prostate cancer patients and is particularly resistant to commonly used chemotherapy and hormonal therapies. Understanding why liver metastasis is associated with poor patient outcomes is important for improving treatment strategies.